8 Most Undervalued Biotech Stocks to Buy Right Now

Why It Matters

These undervalued biotech names offer investors a blend of solid fundamentals, upcoming catalysts, and proven hedge‑fund backing, positioning them for outsized upside in a macro environment where war‑related stimulus is bolstering earnings.

Key Takeaways

• Valneva posted €174.7M revenue (~$192M) and $121M cash.
• Theravance price target raised to $17 after exclusive generic settlement.
• Both have forward P/E under 15 and top hedge‑fund holdings.
• War‑driven stimulus may lift biotech earnings, says Tom Lee.

Pulse Analysis

Tom Lee’s recent CNBC interview underscored an unexpected upside for equities amid a "fog of war." He argued that the surge in U.S. defense spending—from $30 billion to roughly $60 billion a month—injects roughly $12 billion of household‑level cost offset, effectively acting as a fiscal stimulus. For biotech, which often thrives on robust R&D funding and stable cash flows, this macro backdrop can translate into higher valuations and accelerated product pipelines, especially as investors seek defensive growth assets.

The article’s methodology blends quantitative screening with qualitative hedge‑fund sentiment. By filtering for biotech firms with forward price‑to‑earnings ratios below 15 and then ranking by the number of hedge‑fund holders, the list isolates companies that are both cheap on a fundamentals basis and trusted by sophisticated capital managers. Insider Monkey’s data shows that this approach has helped its quarterly newsletter achieve a 498.7% cumulative return since 2014, far outpacing traditional benchmarks. Such a strategy appeals to investors who value crowd‑sourced intelligence and want to capture the upside of under‑followed small‑cap innovators.

Valneva SE and Theravance Biopharma exemplify the type of opportunities the screen uncovers. Valneva reported €174.7 million (≈$192 million) in 2025 revenue, a solid cash pile of €109.7 million (≈$121 million), and anticipates Phase 3 data for its Lyme disease vaccine in early 2026—potentially a catalyst for a market‑price re‑rating. Theravance, meanwhile, saw its price target lifted to $17 after securing an exclusive generic settlement that removes a major commercial overhang, while its YUPELRI® respiratory product hit record profitability. Both stocks sit at the intersection of low valuation, strong balance sheets, and imminent product milestones, making them compelling picks for investors looking to ride the current macro‑driven earnings tailwind.